Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A lit­tle over a year ago when I re­port­ed on Nor­bert Bischof­berg­er’s jump from the CSO job at gi­ant Gilead to a tiny up­start called Kro­nos, I not­ed that with his con­nec­tions in biotech fi­nance, that $18 mil­lion launch round he was start­ing off with could just as eas­i­ly have been $100 mil­lion or more.

With his first an­niver­sary now be­hind him, Bischof­berg­er has that mega-round in the bank.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER